Compare Stocks: ACXP, PSTV, AYTU, and TXMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$1.46 -0.7%	$1.56	$1.33 ▼ $8.34	$6.32M	-2.03	91,265 shs	61,965 shs
AYTU Aytu BioPharma	$2.33 +1.3%	$2.19	$1.65 ▼ $3.07	$24.69M	0.25	23,996 shs	29,029 shs
PSTV Plus Therapeutics	$3.91 -1.3%	$4.34	$2.90 ▼ $23.42	$26.92M	1.4	116,506 shs	63,544 shs
TXMD TherapeuticsMD	$2.09 +1.0%	$2.05	$0.99 ▼ $2.95	$23.96M	0.61	19,758 shs	10,199 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	-0.68%	+2.82%	+0.69%	-30.14%	-71.09%
AYTU Aytu BioPharma	+1.30%	+8.37%	+3.56%	-6.80%	-4.12%
PSTV Plus Therapeutics	-1.26%	+7.12%	-0.26%	-36.11%	-79.42%
TXMD TherapeuticsMD	+0.97%	+2.96%	+6.09%	+5.56%	+89.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$1.46 -0.7%	$1.56	$1.33 ▼ $8.34	$6.32M	-2.03	91,265 shs	61,965 shs
AYTU Aytu BioPharma	$2.33 +1.3%	$2.19	$1.65 ▼ $3.07	$24.69M	0.25	23,996 shs	29,029 shs
PSTV Plus Therapeutics	$3.91 -1.3%	$4.34	$2.90 ▼ $23.42	$26.92M	1.4	116,506 shs	63,544 shs
TXMD TherapeuticsMD	$2.09 +1.0%	$2.05	$0.99 ▼ $2.95	$23.96M	0.61	19,758 shs	10,199 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	-0.68%	+2.82%	+0.69%	-30.14%	-71.09%
AYTU Aytu BioPharma	+1.30%	+8.37%	+3.56%	-6.80%	-4.12%
PSTV Plus Therapeutics	-1.26%	+7.12%	-0.26%	-36.11%	-79.42%
TXMD TherapeuticsMD	+0.97%	+2.96%	+6.09%	+5.56%	+89.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXP Acurx Pharmaceuticals	2.00	Hold	$31.00	2,023.29% Upside
AYTU Aytu BioPharma	2.00	Hold	$10.75	361.37% Upside
PSTV Plus Therapeutics	2.43	Hold	$56.40	1,342.46% Upside
TXMD TherapeuticsMD	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ACXP, PSTV, AYTU, and TXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	ACXP Acurx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PSTV Plus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/6/2026	AYTU Aytu BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/11/2026	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $14.50
6/8/2026	PSTV Plus Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$65.00 ➝ $57.00
5/11/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$2.07 per share	N/A
AYTU Aytu BioPharma	$66.38M	0.38	$0.38 per share	6.13	$2.11 per share	1.10
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
TXMD TherapeuticsMD	$3.02M	8.01	$0.05 per share	44.37	$2.32 per share	0.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXP Acurx Pharmaceuticals	-$7.97M	-$4.05	N/A	N/A	N/A	N/A	-153.92%	-101.69%	8/14/2026 (Estimated)
AYTU Aytu BioPharma	-$13.56M	-$4.58	N/A	9.32	N/A	-60.17%	-69.93%	-13.25%	9/29/2026 (Estimated)
PSTV Plus Therapeutics	-$22.39M	-$2.30	N/A	N/A	N/A	-230.24%	-198.48%	-73.13%	8/13/2026 (Estimated)
TXMD TherapeuticsMD	-$570K	$0.06	34.83	N/A	N/A	5.34%	0.32%	0.23%	8/17/2026 (Estimated)

Latest ACXP, PSTV, AYTU, and TXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	TXMD TherapeuticsMD	-$6.1250	N/A	N/A	N/A	$19.77 million	N/A
8/14/2026	Q2 2026	ACXP Acurx Pharmaceuticals	-$0.42	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	PSTV Plus Therapeutics	-$0.88	N/A	N/A	N/A	$1.11 million	N/A
5/15/2026	Q1 2026	PSTV Plus Therapeutics	-$0.8480	-$1.05	-$0.2020	-$1.05	$0.97 million	$1.03 million
5/13/2026	Q3 2026	AYTU Aytu BioPharma	-$0.4433	-$0.53	-$0.0867	-$0.53	$12.05 million	$12.41 million
5/12/2026	Q1 2026	ACXP Acurx Pharmaceuticals	-$0.59	-$0.62	-$0.03	-$0.62	N/A	N/A
5/12/2026	Q1 2026	TXMD TherapeuticsMD	-$6.1250	$0.01	+$6.1350	$0.01	$19.77 million	$0.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXP Acurx Pharmaceuticals	N/A	3.78	3.78
AYTU Aytu BioPharma	0.27	1.12	1.00
PSTV Plus Therapeutics	N/A	2.27	2.27
TXMD TherapeuticsMD	N/A	3.11	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXP Acurx Pharmaceuticals	11.53%
AYTU Aytu BioPharma	33.49%
PSTV Plus Therapeutics	3.28%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
ACXP Acurx Pharmaceuticals	20.30%
AYTU Aytu BioPharma	4.90%
PSTV Plus Therapeutics	2.50%
TXMD TherapeuticsMD	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXP Acurx Pharmaceuticals	3	4.30 million	3.43 million	No Data
AYTU Aytu BioPharma	160	10.73 million	10.21 million	Not Optionable
PSTV Plus Therapeutics	20	6.88 million	6.71 million	Not Optionable
TXMD TherapeuticsMD	420	11.57 million	11.38 million	Optionable

ACXP, PSTV, AYTU, and TXMD Headlines

Recent News About These Companies

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains

June 5, 2026 | marketwatch.com

TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives

May 12, 2026 | tipranks.com

TherapeuticsMD Announces First Quarter 2026 Financial Results

May 12, 2026 | businesswire.com

TherapeuticsMD Inc. stock outperforms competitors on strong trading day

April 6, 2026 | marketwatch.com

TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy

April 2, 2026 | theglobeandmail.com

TherapeuticsMD Explains Brief Delay In Annual Filing

April 1, 2026 | tipranks.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | finance.yahoo.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | businesswire.com

TherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 Shares

December 30, 2025 | insidertrades.com

TherapeuticsMD approves key proposals at annual meeting

December 16, 2025 | msn.com

TherapeuticsMD: Q3 Earnings Snapshot

November 13, 2025 | timesunion.comT

TherapeuticsMD Reports Q3 2025 Financial Results

November 13, 2025 | msn.com

TherapeuticsMD Announces Third Quarter 2025 Financial Results

November 12, 2025 | businesswire.com

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, PSTV, AYTU, and TXMD Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

$1.46 -0.01 (-0.68%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$1.46 0.00 (-0.34%)

As of 08/6/2026 06:37 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Aytu BioPharma NASDAQ:AYTU

$2.33 +0.03 (+1.30%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$2.31 -0.02 (-1.07%)

As of 08/6/2026 04:10 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Plus Therapeutics NASDAQ:PSTV

$3.91 -0.05 (-1.26%)

As of 08/5/2026

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

TherapeuticsMD NASDAQ:TXMD

$2.09 +0.02 (+0.97%)

As of 08/6/2026 04:00 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACXP, PSTV, AYTU, and TXMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACXP, PSTV, AYTU, and TXMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACXP, PSTV, AYTU, and TXMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, PSTV, AYTU, and TXMD Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

Aytu BioPharma NASDAQ:AYTU

Plus Therapeutics NASDAQ:PSTV

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACXP, PSTV, AYTU, and TXMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACXP, PSTV, AYTU, and TXMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACXP, PSTV, AYTU, and TXMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, PSTV, AYTU, and TXMD Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

Aytu BioPharma NASDAQ:AYTU

Plus Therapeutics NASDAQ:PSTV

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools